Summit Securities Group’s AnaptysBio ANAB Stock Holding History

Summit Securities Group’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-170	Closed	-$5.21K	–	1004
2025 Q3	$5.21K	Buy	+170	New	+$3.9K	﹤0.01%	920

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Summit Securities Group's ANAB Position: Q4 2025 in Review

Summit Securities Group sold out of AnaptysBio (ANAB) in Q4 2025, closing a stake of 170 shares — an estimated $5.21K sold.

Summit Securities Group first reported a position in ANAB in Q3 2025 and held it in 1 quarter. The position peaked at $5.21K in Q3 2025. 179 funds tracked by Wall St. Rank hold ANAB as of Q4 2025.

Summit Securities Group reported no remaining AnaptysBio position as of Q4 2025 after selling out during the quarter.
Summit Securities Group sold 170 AnaptysBio shares in Q4 2025, an estimated $5.21K.
Summit Securities Group first reported a position in AnaptysBio in Q3 2025 and held it in 1 quarter.
Summit Securities Group's AnaptysBio position peaked at $5.21K in Q3 2025.
179 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2025.

Based on Summit Securities Group's 13F filing for Q4 2025, filed 17 Feb 2026.